Search clinical trials for: BMS-767778 or Placebo

Total 1189 results

Bristol-Myers Squibb

Terminated

A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis

Rheumatoid Arthritis | Inflammatory Bowel Diseases | Psoriasis | Nonalcoholic Steatohepatitis | Ankylosing Spondylitis

Netherlands
Bristol-Myers Squibb

Completed

Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects

Severe Sepsis

United States
Bristol-Myers Squibb

Completed

A Study of BMS-986171 in Healthy People to Assess Safety, to Measure Blood Levels of Drug, and to Find Out What the Drug Does to the Body

Liver Fibrosis/NASH

United States
Bristol-Myers Squibb

Withdrawn

A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Scleroderma

United Kingdom, United States, Poland, Canada
Bristol-Myers Squibb

Completed

Safety Study of BMS-770767 in Subjects With Hypercholesterolemia

Dyslipidemia

Canada, Australia, United States
Bristol-Myers Squibb

Completed

Safety Study to Evaluate BMS-830216 in Healthy Subjects

Obesity

United States
Samjin Pharmaceutical Co., Ltd.

Completed

A Phase 1 Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers

Healthy

Korea, Republic of
Shenzhen People's Hospital

Unknown

Bioabsorbable Scaffold vs Drug-coated Balloon for Coronary de Novo Lesions in STEMI: Prospective Observational Trial (NeovasvsDCB)

Cardiovascular Diseases

China
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986454 in Healthy Participants

Healthy Participants

United Kingdom
Bristol-Myers Squibb

Active, not recruiting

A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis

Psoriasis

United States, Australia, Canada, Japan, United Kingdom
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Terminated

A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Withdrawn

A Single and Multiple Ascending Dose Study of BMS-986318 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study to Test the Effects of BMS-986036 on the Body in Healthy Japanese and Non-Japanese Subjects

Metabolics

United States
Bristol-Myers Squibb

Completed

Safety and Tolerability Study of BMS-986177 in Healthy Subjects

Thrombosis

Belgium
Bristol-Myers Squibb

Completed

Crossover Post-herpetic Neuralgia (PHN)

Post-Herpetic Neuralgia (PHN)

United States, France
Bristol-Myers Squibb

Completed

Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects

Obesity

United States
Bristol-Myers Squibb

Completed

BMS-741672 for Diabetic Neuropathic Pain

Neuropathic Pain

United States
Bristol-Myers Squibb

Completed

A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Sweden, United States, Denmark, Finland
Bristol-Myers Squibb

Completed

Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy Subjects

Healthy

United States
Bristol-Myers Squibb
Solvay Pharmaceuticals

Terminated

Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects

Obesity

United States
Hospital Ambroise Paré Paris

Completed

Comparison of the Efficacy of rTMS and tDCS of the Motor Cortex in Patients With Chronic Neuropathic Pain

Lumbar Radiculopathy

France
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Cardiomyopathy, Hypertrophic

United States, Australia, Canada, France, Germany, Ireland, Italy, Spain, United Kingdom
Bristol-Myers Squibb

Completed

To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants

Thrombosis

United States
Bristol-Myers Squibb

Withdrawn

A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean Participants

Healthy Participants

China, Korea, Republic of
Biogen

Terminated

Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PASSPORT)

Supranuclear Palsy, Progressive

United States, France, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, Austria, Canada, Germany, Japan, Australia, Greece
Bristol-Myers Squibb

Completed

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Soft Tissue Sarcoma | Transitional Cell Carcinoma | Advanced Non-small Cell Lung Cancer | Gastric/Esophageal Adenocarcinoma | Pancreatic Cancer Including Ampulla of Vater

United States, Argentina, Germany, Belgium, Canada, Poland, Netherlands, United Kingdom, France
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants

Healthy Participants

Germany
Bristol-Myers Squibb

Terminated

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease

Nonalcoholic Fatty Liver Disease

United States
Bristol-Myers Squibb

Withdrawn

Proof of Concept Study of BMS-823778 to Assess the Effects on Atherosclerosis

Atherosclerotic Cardiovascular Disease
Bristol-Myers Squibb

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

Taiwan, United States, China, Brazil, Japan, Poland, Mexico, Ireland, France, Argentina, Australia, Germany, Chile, Colombia, India, Puerto Rico, Romania, Spain, United Kingdom
Biogen

Completed

Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy (CN002-003)

Progressive Supranuclear Palsy

United States
Bristol-Myers Squibb

Terminated

A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease

Alzheimer's Disease

Sweden, United States, Canada, Denmark, France, Finland
Arthrosi Therapeutics

Completed

Multiple Ascending Dose Study of AR882 in Healthy Adult Male Volunteers

Healthy Volunteers

Australia
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Recruiting

A First-in-Human Study of QY211 Gel in Adult Subjects

Atopic Dermatitis

China
HK inno.N Corporation

Unknown

A Study to Explore Pharmacokinetics/Pharmacodynamics and Safety of Tegoprazan BID Dosing in Healthy Subjects

Healthy

Korea, Republic of
CSL Behring

Completed

Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

Arthritis, Psoriatic

Italy, United States, Canada, Mexico, Poland, Spain, Germany, Czechia, Russian Federation, Australia, South Africa, Argentina, Hungary
Allyx Therapeutics
Yale University; National Institute on Aging (NIA)

Recruiting

A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease

Alzheimer's Disease

United States
Celgene

Terminated

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult Participants

Healthy Volunteers

Belgium
Bristol-Myers Squibb

Completed

Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure (STANDUP AHF)

Heart Failure

France, Germany, Japan, Spain, United States, Argentina, Poland, Italy, Czechia, Greece, Netherlands, Canada, United Kingdom
Bristol-Myers Squibb

Completed

Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial

Hepatitis C

United States, Australia, France, Japan, Spain, Sweden, Canada, Germany, Mexico, Denmark, Italy, Korea, Republic of, Taiwan, Argentina, Brazil, Ireland, Poland, Puerto Rico, United Kingdom
Huabo Biopharm Co., Ltd.

Completed

A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

China
Pfizer

Terminated

Study Evaluating Safety Of BMP-655/ACS As An Adjuvant Therapy For Rotator Cuff Repair

Rotator Cuff Tear

Germany, Netherlands
Bristol-Myers Squibb

Completed

Single Ascending Dose (BMS-813160) Study

Accelerated Intimal Hyperplasia

United States
Creabilis SA
LCG Bioscience

Completed

A Study to Assess the Pharmacokinetics, Safety and Tolerability of CT327 in Healthy Male Volunteers

Safety
Intron Biotechnology, Inc.

Completed

A Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of KMRC011

Acute Radiation Syndrome

Korea, Republic of
Pfizer

Terminated

A Single Dose Study Of PF-06291874 In Healthy Adult Subjects

Healthy

United States
Akesobio Australia Pty Ltd

Completed

A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis

Atopic Dermatitis

New Zealand, Australia
Bristol-Myers Squibb

Completed

An Ascending Dose Study of BMS-986259 to Study Safety in Healthy Participants

Healthy Participants

United Kingdom, Netherlands
Bristol-Myers Squibb

Completed

Multiple Dose Japanese Bridging Study

Alzheimer Disease

United States

3

Subscribe